If they weren't excellent than the pps wouldn't have re-rate from 4c to 15c and the lead presenter wouldn't have mention the efficacy seen with low dosage and @Mason14 wouldn't have said it was excellent result to archive a CR on very low dosage.
You clearly still don't know the treatment cost for Cholangiocarcinoma. IMU's revenue will be $100M with just 10% of the market in the US for DLBCL (18K diagnosis yearly using conservative treatment cost which is currently quite expensive) and Cholangiocarcinoma (8K diagnosis yearly using conservative treatment cost which is currently quite expensive) and the average EPS ratio for biotech stock is 10-15 (some says it's as high as 20). So maybe I'm wrong and it's really worth $2B and not $1B.......
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)